DMPK and myotonic dystrophy type 1: In preclinical testing (data currently unpublished), the compound was reported to be successfully delivered to skeletal, cardiac and smooth muscles in both mouse and cynomolgus monkeys, producing a reduction in DMPK RNA expression and an amelioration of the disease phenotype in DM1 mice.